ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1609

Circulating 25-Hydroxyvitamin D Level and Risk of Developing Rheumatoid Arthritis

Linda T. Hiraki1, Jing Cui2, Susan Malspeis3, Karen H. Costenbader3 and Elizabeth W. Karlson4, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: 25-hydroxyvitamin D and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Vitamin D has demonstrated immunomodulatory properties with potential etiologic implications for autoimmune diseases including rheumatoid arthritis (RA). However, a causal association between decreased vitamin D levels and increased RA risk has yet to be definitively demonstrated. Cross-sectional studies are not able to rule-out reverse causation. We examined the relationship between circulating 25-hydroxyvitamin D (25(OH)D) and incident RA in 2 nested case-control studies, in the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) cohorts.

Methods: We conducted a nested case-control investigation of incident RA in prospective cohorts the NHS and NHSII. We included 170 cases with blood samples collected from at least 3 months to 14 years prior to RA diagnosis, each matched to 3 controls on age, menopausal status, postmenopausal hormone use, date, time and fasting status of blood draw. 25(OH)D levels measured by chemiluminescence immunoassay. We used conditional logistic regression to calculate the odds ratio (OR) and 95% confidence intervals for incident RA for continuous 25(OH)D, dichotomous levels categorized as insufficient(<=20ng/mL) vs. sufficient 25(OH)D and quartile cutoffs of 25(OH)D, using age-adjusted and multivariable adjusted models. We repeated the analyses stratified by categories of time between the blood draw and RA diagnosis (3 months to < 4 years, 4 years to < 8 years and >8 years). Random effects models were used to meta-analyze estimates of association from the two cohorts.

Results: Incident RA was confirmed in 123 NHS and 47 NHSII participants. Mean age at RA diagnosis was 64.3 ± 7.9 years for NHS and 49.4 ± 5.2 years for NHSII, 60% were rheumatoid factor positive. Mean time from blood draw to RA diagnosis was 8.3 ± 4.8 years for NHS and 5.0 ± 2.7 years for NHSII. Meta-analysis of crude and multivariable-adjusted conditional logistic models did not show significant associations between circulating 25(OH)D levels (continuously, dichotomously or in quartiles) and odds of RA. However, there was a 25% increased odds of developing RA with every 1ng/ml decrease in circulating 25(OH)D [OR 1.25 (95% CI 1.01, 1.54)] among those NHSII women who had blood analyzed between 3 months and <4 years prior to RA diagnosis (Table). There was no association between 25(OD)D levels and RA in longer time intervals to diagnosis.

Conclusion: We did not find a significant overall association between circulating 25(OH)D levels and odds of developing RA among women in NHS and NHSII.  However, we did detect an increased odds of RA associated with low 25(OH)D among women in the NHSII cohort only, with levels measured closest to RA diagnosis (>3months to <4 years). These results suggest that vitamin D levels fall in the time windows closest to RA diagnosis and may represent reverse causation.


Table: Odds ratios and 95% confidence intervals for rheumatoid arthritis associated with a 1ng/mL decrease in 25-hydroxyvitamin D

NHS

NHSII

Pooled results

N cases

N controls

OR (95% CI)

p-value

N cases

N controls

OR (95% CI)

p-value

OR (95% CI)

p-value

p-heterogeneity

Total

123

368

0.99 (0.96, 1.02)

0.51

47

138

1.02 (0.97, 1.07)

0.42

1.00 (0.97, 1.02)

0.9

0.3

Sero+ve

63

186

1.00 (0.95, 1.04)

0.83

27

79

1.03 (0.95, 1.12)

0.51

1.00 (0.97, 1.04)

0.91

0.5

3mo-<4y

30

93

1.06 (0.97, 1.03)

0.21

24

69

1.25 (1.01, 1.54)

0.04

1.12 (0.96, 1.03)

0.16

0.15


Disclosure:

L. T. Hiraki,
None;

J. Cui,
None;

S. Malspeis,
None;

K. H. Costenbader,
None;

E. W. Karlson,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-25-hydroxyvitamin-d-level-and-risk-of-developing-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology